JUNE 11, 2020
Grants Awarded 

Extramurally funded research grants awarded to Rogel Cancer Center members

Program Key:
CB - Cancer Biology; CG - Cancer Genetics; CHI - Cancer Hematopoiesis and Immunology; DT - Developmental Therapeutics; HBO - Health Behavior and Outcomes; CEP - Cancer Epidemiology and Prevention; TACR - Translational and Clinical Research
In the spotlight
From Cancer Epidemiology and Prevention
Dana Dolinoy, Ph.D., was awarded a $6.9M R35 Outstanding Investigator Award from the National Institute of Environmental Health Sciences for “Environmental epigenomics and precision environmental health." Dr. Dolinoy’s research will expand the repertoire of human epigenome editing tools resulting in therapeutics to treat a broad array of environmental and epigenetic diseases including imprinted gene disorders and cancer.
From Cancer Hematopoiesis and Immunology
The National Cancer Institute awarded Weiping Zou, M.D., Ph.D., Co-Leader of the Rogel Cancer Center Cancer Hematopoiesis and Immunology Program and Director of the Rogel Cancer Center Center of Excellence for Immunology and Immunotherapy, with a $3.2M R01 for “Metabolic impact on T cell-mediated cancer immunity and therapy." This project aims to mechanistically, functionally, and clinically test hypotheses that 1) methionine metabolic circuit controls effector T cell survival and polyfunctionality in the tumor microenvironment, and that 2) specific histone alteration mechanistically connects with effector T cell-mediated anti-tumor immunity.
From Health Behavior and Outcomes and Cancer Epidemiology and Prevention
Multi-PI, inter-programmatic, $1.4M R01 awarded by the NCI to Ted Skolarus, M.D., and Alexander Tsodikov, M.Sc., Ph.D., for “Refining castration use for recurrent prostate cancer." This study will combine population-based cancer registry and electronic record data from a national delivery system with biostatistical modeling and randomized trial data to examine the impact of castration with ADT on progression and survival after localized prostate cancer treatment.
Other $100K+ Extramural Grants Awarded in May
NCI
Costas Lyssiotis, Ph.D. : R01 ($2M) “Targeting metabolic stress to induce pancreatic tumor cell death” (CB)
Scott Larsen, Ph.D. : R01 SubK [Overall PIs: Ronald Buckanovich and Anda Vlad (Magee-Womens Research Institute)] ($212K) “ALDH inhibition as modulator of tumor immunobiology” (DT)
 
Other NIH
Pavan Reddy, M.D. : NHLBI R01 ($2.4M) “COPII dependent regulation of T cell alloimmunity” (CHI)
 
Other External
Larry Antonuk, Ph.D. : $560K SubK from Los Alamos National Laboratory (Prime Sponsor: Department of Energy) for “ASD scintillator optimization” (TACR)
Please forward this message to your fellow cancer center colleagues.
M-LINE 800-962-3555 | BLOG michiganhealthlab.org